Victoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk
Munich, Germany, 15 September 2016 - Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults with type 2 diabetes at high cardiovascular (CV) risk. Similar significant results were observed between Victoza® and placebo across subgroups (with no, mild or moderate renal impairment).1 The results were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1
Further information
| Media: | ||
| Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
| Åsa Josefsson | +45 3079 7708 | aajf@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
| Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
References
1. Results of the liraglutide effect and action in diabetes - evaluation of cardiovascular outcome results (LEADER) trial. Scientific Sessions at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. 15 September 2016.
Attachment